ArticleCNS neuroscience & therapeutics2025
Transcranial iTBS Combined With Trans-Spinal iTBS Targeting PDE1A/cAMP/PKA Axis Regulates Neural Regeneration After Spinal Cord Injury.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transcranial iTBS Combined With Trans-Spinal iTBS Targeting PDE1A/cAMP/PKA Axis Regulates Neural Regeneration After Spinal Cord Injury.CNS neuroscience & therapeutics · 2025Article
- Efficacy of dual-target iTBS on gait function and brain activation in stroke patients: a randomized, single-blinded, sham-controlled study.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsTo explore the impact of intermittent theta burst stimulation (iTBS) treatment at various targets on spinal cord injury (SCI), as well as the effects of dual-target iTBS therapy on neurological functional recovery in rats with SCI and its underlying mechanisms.
methodsUsing an improved Allen's method, an incomplete C6 SCI model was established. Postoperatively, the rats with SCI underwent transcranial iTBS, trans-spinal iTBS, or dual-target iTBS. Neurological functional recovery and synaptic function following SCI were evaluated through behavioral tests, footprint analysis, electrophysiological assessments, pathological staining, transmission electron microscopy, Golgi staining, and immunofluorescence staining. The expression of relevant proteins and genes was assessed using Western blotting and qRT-PCR. Proteomic and metabolomic sequencing analyses of spinal cord tissue from each group were conducted to investigate specific mechanisms. Additionally, lentivirus was used to infect primary neurons to elucidate the effect of PDE1A. Furthermore, lentivirus was applied to SCI rats to explore the influence of PDE1A on neurological and synaptic functions following SCI.
resultsCompared with the single-target iTBS group, dual-target iTBS treatment significantly improved motor function and reduced the damaged area of the spinal cord in SCI rats. Following dual-target iTBS intervention, SCI rats exhibited improvements in neural function and synaptic function. Sequencing analysis identified the protein PDE1A present in all groups, and the protein interaction network revealed that PDE1A is involved in the cAMP signaling pathway, with an increase in PDE1A expression observed after SCI. Additionally, inhibiting PDE1A promoted the expression of cAMP and protein kinase cAMP-activated catalytic subunit alpha (PRKACA) in primary neurons, thereby facilitating synapse function in primary neurons. Inhibition of PDE1A also improved neural connection and synaptic reconstruction in SCI rats.
conclusionCompared with single-target iTBS treatment, dual-target iTBS treatment promotes the recovery of motor function and spinal cord tissue repair more effectively in SCI rats. Dual-target iTBS may promote neural regeneration and synaptic remodeling after SCI by regulating the PDE1A-cAMP-PKA signaling pathway, thereby improving neurological dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.